Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02034591 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT02034591 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 37 participants.
The verdict
NCT02034591, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the bioavailability of Apixaban oral solution administered through an Nasogastric Tube (NGT) in the presence of Boost® Plus and Apixaban administered as crushed tablet through a nasogastric tube relative to Apixaban solution administered orally in healthy subjects.
Interventions
- DRUG Apixaban
- DIETARY_SUPPLEMENT Boost Plus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2011-10 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02034591
The ClinicalTrials.gov registry entry for NCT02034591 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Apixaban is the first listed.
NCT02034591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02034591 about?
NCT02034591 is a clinical study titled "Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects". The purpose of this study is to assess the bioavailability of Apixaban oral solution administered through an Nasogastric Tube (NGT) in the presence of Boost® Plus and Apixaban administered as crushed tablet through a nasogastric tube relative to Apixaban solution administered orally in healthy subje...
What is the current status of trial NCT02034591?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2011-10. Estimated completion is 2011-11.
What interventions are being tested in trial NCT02034591?
The interventions under investigation include: Apixaban (DRUG), Boost Plus (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02034591?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.